HNSA-5487, Hansa Biopharma’s experimental treatment for neuromyelitis optica spectrum disorder (NMOSD) and other autoimmune diseases, safely and effectively reduced the levels of immunoglobulin G (IgG) antibodies — ones involved in the abnormal immune attacks that drive these conditions — in a Phase 1 clinical trial involving healthy volunteers.
Drug information
Maintenance treatment with rituximab significantly reduced the number of relapses per year in people with neuromyelitis optica spectrum disorder (NMOSD), and it remained effective after patients experienced relapses, according to a study from China. Relapses more frequently occurred within the first year after rituximab initiation, and their frequency decreased…
Enspryng (satralizumab-mwge) promotes an anti-inflammatory profile in plasmablasts, the immune cells that produce large amounts of the self-reactive antibodies that drive most cases of neuromyelitis optica spectrum disorder (NMOSD). That’s according to a study analyzing immune cells from NMOSD patients before and after treatment with Enspryng, as well…
Most neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) remain free of relapses for at least a year, with some being able to stop treatment with oral glucocorticoids, according to a study of real-world data. The findings are consistent with those of SAkuraStar (NCT02073279)…
Tocilizumab, an anti-inflammatory medication used off-label for neuromyelitis optica spectrum disorder (NMOSD), can help prevent relapses (flare-ups) and ease disability while being generally safe, according to a meta-analysis. The study, “Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety,” was published in the journal…
Uplizna (inebilizumab) prevented disease attacks for people with neuromyelitis optica spectrum disorder (NMOSD) regardless of whether they had a genetic variant in the FCGR3A gene that’s associated with reduced efficacy of rituximab, a therapy commonly used off-label for NMOSD. That’s according to additional data analyses from the Phase…
Long-term use of the approved therapy Soliris (eculizumab) safely and effectively prevents relapses in the real world in people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the AQP4 protein. That’s according to two-year interim data from an observational study in Japan, where Soliris was approved in…
In rare cases, people with neuromyelitis optica spectrum disorder (NMOSD) can experience low blood levels of neutrophils, a type of immune cell, a few weeks after receiving anti-CD20 therapy. Researchers have reported the case of a NMOSD patient who developed the uncommon side effect, called late-onset neutropenia, four…
An analysis of pharmacological data supports the observed clinical efficacy of Soliris (eculizumab) in significantly reducing relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) given the therapy in the PREVENT Phase 3 clinical trial. At its approved dose, Soliris led to rapid, sustained, and complete suppression…
SB12, Samsung Bioepis’ biosimilar candidate of Soliris (eculizumab), is comparable to the original medication in terms of safety, pharmacological properties, and immunoreactivity profile, according to data from a Phase 1 clinical trial in healthy volunteers. Soliris, by Alexion Pharmaceuticals, is an approved therapy for a number of conditions,…
Recent Posts
- 2 approved treatments for NMOSD may work better than off-label one
- It’s important to realize when the caregiver needs care
- MRI scan of waste system in brain may track NMOSD severity, progression
- My mom’s example of strength still guides me in life with NMOSD
- Short course of approved drug effective for treatment-resistant NMOSD